Takeda signs 12-year renewable energy agreement in US

By Ben Hargreaves

- Last updated on GMT

© franckreporter / Getty Images
© franckreporter / Getty Images

Related tags Takeda Renewable energy

Adding to broader action being taken across the industry, the company has signed an agreement with Enel for the supply of renewable energy credits covering its electricity needs across the US.

The 12-year agreement between Takeda and Enel North America is part of the former’s effort to reduce its emissions of scopes one and two greenhouse gas by 40% before 2025.

The ‘virtual power purchase agreement’ (VPPA) sees Takeda acquire 350,000 megawatts of electricity annually from Enel’s wind project that is based in Oklahoma, US.

Rather than purchasing the power for direct use, the project is a ‘strategic means’ for Takeda to support the use of wind power at scale, a spokesperson for the company told Outsourcing Pharma. “The agreement accommodates making renewable energy available to the electric grid for broad use,” they added.

The scale of the purchase agreement meets all of the electricity usage needs for Takeda’s footprint in the US, including manufacturing facilities, as well as supply centers, R&D facilities, and other office spaces. The company noted that the agreement would also cover existing plans for expansion of these locations.

Overall, the ambition is for Takeda to achieve net-zero greenhouse gas emissions for scopes one and two before 2035, with a final aim of being net-zero throughout its value chain, including scope three emissions, before 2040. With this agreement, the company will be able to reduce approximately 20% of its current emissions.

According to the company’s spokesperson, Takeda was carbon neutral for the first time in 2020, during fiscal year 2019, across its value chain for scopes one and two.

The spokesperson added, “Takeda has a large operational footprint in the US and, while today’s announcement is for a VPPA in the US, we are looking to initiate similar projects in other regions in which Takeda operates to continue to progress towards achieving the company’s net-zero goals.”

Renewable focus

The action by Takeda is part of a broader movement across the larger companies in the industry to rely on the greater use of renewable energy. Previously, Novo Nordisk had invested in a 672-acre solar panel installation​ to provide power to its operations in the US.

Novo Nordisk is part of RE100, which is formed of a group of businesses that aims to be 100% powered be renewable energy. The organization also contains AstraZeneca, Biogen, and Johnson & Johnson, among other pharma companies.

A group of scientists from Genentech, GSK, and Merck also recently published a paper​ on drug substance manufacturing and highlighted how manufacturing facilities electricity consumption is the largest driver behind the industry’s environment impact. The research called for a focus on process intensification, due to the resulting reduction in processing times and higher yields produced.

Related news

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Content provided by Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

Enhance your cGMP chemical supply chain

Enhance your cGMP chemical supply chain

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 09-Feb-2023 | White Paper

Supply chain issues have real, quantifiable impacts on biomanufacturers. However, the right support can make a cGMP supply chain operate seamlessly. Thermo...

Related suppliers

Follow us

Products

View more

Webinars